Jim Cramer: This Energy Stock Is A Buy, Stay Away From DexCom
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.
On CNBC’s “Mad Money Lightning Round,” Jim Cramer said Oneok (NYSE:OKE) is “terrific” and recommended buying more of the stock.
On Aug. 5, ONEOK reported better-than-expected second-quarter GAAP EPS results, posting quarterly earnings of $1.33 per share which beat the analyst consensus estimate of $1.21 per share.
Don’t miss out on the next NVIDIA – you can invest in the future of AI for only $10.
**This is a paid advertisement. Carefully consider the investment objectives, risks, charges and expenses of the Fundrise Innovation Fund before investing. This and other information can be found in the Fund’s prospectus. Read them carefully before investing.
“The problem with Dollar Tree (NASDAQ:DLTR) is that people I think have discovered that the small form is no longer working, they would rather go to Walmart (NYSE:WMT), which is a buy, or Costco (NASDAQ:COST) if they can afford the membership fee,” he said.
On July 16, Piper Sandler analyst Peter Keith downgraded the rating for Dollar Tree from Overweight to Neutral and lowered the price target from $143 to $112.
The “Mad Money” host recommended staying away from Dexcom, Inc. (NASDAQ:DXCM). “Dexcom had a real bad miss. They still really haven’t fully explained why that is,” he noted.
Dexcom specializes in selling continuous glucose monitors.
Trending: Mark Cuban believes “the next wave of revenue generation is around real estate and entertainment” — this new real estate fund allows you to get started with just $100.
On Aug. 5, Baird analyst Jeff Johnson downgraded the company from Outperform to Neutral and slashed the price target from $161 to $80.
When asked about KeyCorp (NYSE:KEY) , he said, “Definitely keep Key. Key is very, very strong, a terrific, terrific bank.”
Cramer said he would be a buyer of CRISPR Therapeutics AG (NASDAQ:CRSP).
On Aug. 5, CRISPR Therapeutics posted a narrower-than-expected quarterly loss.
Read More:
This article Jim Cramer: This Energy Stock Is A Buy, Stay Away From DexCom originally appeared on Benzinga.com
